Insulin analogues have clinical and cost benefits
Insulin analogues look set for a far wider role in the NHS after a new analysis found they had both clinical and cost benefits.
The study of records from 300 GP practices found insulin glargine improved outcomes in type 2 diabetes and cut hypoglycaemic events by 25 per cent compared with insulin detemir.
Study author Dr Craig
Currie, honorary research
fellow at the school of medicine, Cardiff University, compared glargine to neutral protamine Hagedorn (NPH) insulin and insulin detemir. In both cases it proved cost-effective.
Comparing it with NPH, Dr Currie said: 'Insulin glargine resulted in significant health benefits and represents excellent value for money for the treatment of type 2 diabetes.'
Simon Dixon, senior lecturer in health economics at the School of Health and Related Research in Sheffield, said: 'The findings suggest glargine is cost-effective in both type 1 and type 2 diabetes, not just in type 1 as concluded by the original economic appraisal of glargine by NICE in 2002.'